Pharmaceutical Executive
Its use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making.
Barbara Arone
Advertisement
Articles by Barbara Arone
Advertisement
Latest Updated Articles
The Argument for External Comparator AdoptionJune 28th 2019
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
3
What Governance Resets Should Pharma Companies Take in Response to AI?
4
Conflict in Middle East Disrupts Pharma Drug Supplies: Report
5